Toronto Dominion Bank Sells 26,368 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Toronto Dominion Bank trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 19.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 107,834 shares of the pharmaceutical company's stock after selling 26,368 shares during the period. Toronto Dominion Bank's holdings in Vertex Pharmaceuticals were worth $43,424,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in VRTX. Brown Lisle Cummings Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth about $30,000. Golden State Wealth Management LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth $37,000. Truvestments Capital LLC boosted its holdings in shares of Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after buying an additional 23 shares in the last quarter. Mpwm Advisory Solutions LLC purchased a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $40,000. Finally, Midwest Capital Advisors LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This trade represents a 10.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on VRTX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Barclays raised their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Bank of America increased their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Finally, Royal Bank of Canada increased their price target on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $515.04.

Vertex Pharmaceuticals Stock Up 0.4%

VRTX traded up $1.99 during midday trading on Thursday, hitting $447.09. 882,371 shares of the company's stock traded hands, compared to its average volume of 1,416,283. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The stock's fifty day simple moving average is $472.28 and its 200-day simple moving average is $461.84. The company has a market cap of $114.81 billion, a PE ratio of -203.22, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The company's revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $4.76 EPS. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.